Impurities found in Sanofi heparin product

While heparin maker Baxter mulls whether to re-enter the market for that blood thinner, Sanofi-Aventis is announcing that small amounts of an impurity have been found in batches of its heparin injection Lovenox. Batches of contaminated Lovenox have been found in the U.K. and in Sweden, where it is sold under the name Clexane. European regulators said that there's no evidence of any risk to patients, but Sweden has withdrawn the product anyway as a precaution.

Back in Chicago, Baxter CEO is saying that the company is leaving its heparin options open. You'll recall that Baxter recall virtually all its heparin products after the med was linked to severe allergic reactions and deaths; since then, investigators found a contaminant in the problem batches and have said they suspect it was introduced somewhere along the med's Chinese supply chain.

Before deciding whether to sell heparin vials again, CEO Robert Parkinson told analysts, the company needs to understand how the product was contaminated in the first place. "We need to ensure that that supply chain is controlled as effectively as possible," he said.

- check out the Sanofi story in the Wall Street Journal
- see the piece on Baxter in the Chicago Tribune

Suggested Articles

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Novartis hopes to leverage its existing presence in the hematology community to achieve a successful launch of Adakveo.

AstraZeneca's Farxiga is touting its heart failure data in patients with or without diabetes, but results in non-diabetics looks particularly strong.